zintick

Arcus Biosciences RCUS

Arcus Biosciences, Inc. · NYSE · Pharmaceutical Preparations

$18.39+1.38%close on Oct. 28, 2026 · volume 2.0M · Yahoo Finance

Price, last 47 sessions

$20.00$25.00$30.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 28, 2026 · high $31.57 · low $17.76 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Aug. 21, 2026Alexander Azoy
Chief Accounting Officer
Sold
10b5-1 plan
2,827$30.00$84,810

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 9 →
  • 8-KOct. 23, 2026, 4:12 p.m. ETView on SEC.gov

    Other events · Financial statements and exhibits

    AI summary, unreviewedArcus Biosciences Prices $250 Million Share Offering at $17.50, Closes $269.7 Million Net Proceeds After Full Overallotment

  • 424B5Oct. 22, 2026, 4:05 p.m. ETView on SEC.gov
  • 424B5Oct. 21, 2026, 4:30 p.m. ETView on SEC.gov
  • 8-KOct. 21, 2026, 4:09 p.m. ETView on SEC.gov

    Results of operations and financial condition

    AI summary, unreviewedArcus Biosciences Estimates $694.0 Million Cash and Marketable Securities as of September 30, 2026 in Preliminary, Unaudited Update

  • 8-KOct. 20, 2026, 8:33 a.m. ETView on SEC.gov

    Other events

    AI summary, unreviewedArcus Biosciences Presents ARC-20 Casdatifan Data in Renal Cell Carcinoma, Reporting 50% First-Line cORR and 14.5-Month Second-Line Median PFS

  • 4Aug. 24, 2026, 5:52 p.m. ETView on SEC.gov
  • SCHEDULE 13D/AAug. 7, 2026, 4:30 p.m. ETView on SEC.gov
  • 10-QAug. 5, 2026, 4:11 p.m. ETView on SEC.gov